Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
Ontology highlight
ABSTRACT: Despite aggressive chemoradiation (CRT) protocols in the treatment of patients with head and neck squamous cell carcinomas (HNSCC), the outcome is still unfavorable. To improve therapy efficacy we had already successfully tested the multikinase inhibitor sorafenib in combination with irradiation (IR) in previous studies on HNSCC cell lines. In this study we investigated its effect on combined CRT treatment using cisplatin.Radio- and chemosensitivity with and without sorafenib was measured in four HNSCC cell lines and normal fibroblasts (NF) by colony formation assay. Apoptosis and cell cycle analysis were performed by flow cytometry.In HNSCC cells, sorafenib enhanced the antiproliferative effect of cisplatin without affecting apoptosis induction and with only minor effects on cell inactiva
SUBMITTER: Mockelmann N
PROVIDER: S-EPMC5029646 | biostudies-literature | 2016 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA